Alluvi, known as BI 4744, offers a promising development in obesity therapy. This dual activator targeting both GLP-1 and GIP receptors demonstrates impressive effectiveness in research assessments, arguably exceeding https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/